Longevity covers therapeutics, robotics, and fintech. Yet as an emerging industry how do these get financed when they are so risky? How should venture firms evaluate longevity companies and how should founders attract investors and employees? This symposium will look at these questions specifically as applied to longevity, uniquely from the investor, scientist, and the founder viewpoint. The symposium will provide a foundation to the field with talks from investors, scientists and company founders who will explain their respective perspectives, and will include talks from Stanford faculty involved with startups and spinouts.

REGISTER to attend virtually and request in-person attendance on Eventbrite. 


 

8 AM - 9 AM: Registration & Networking

●      Coffee

9am: Conference Welcome: 

Anastasiya Giarletta

9:10am: Aging Science and Technology

●      Ronjon Nag, PhD, Adjunct Professor in Genetics, Stanford; Instructor in Stanford courses: Longevity Science and technology;  Longevity Venture Capital

9.40am: Biomarkers and Ageotypes

●      Michael Snyder, Professor Stanford University, Chair, Dept. of Genetics; Director, Center for Genomics and Personalized Medicine 

10:10am: Brain Aging

●      Tony Wyss-Coray, D.H. Chen Distinguished Professor of Neurology and Neurological Sciences and the Director of the Phil and Penny Knight Initiative for Brain Resilience at Stanford University

10:40am: Break

11:15am: Female Brain Aging

●      Dena Dubal, Associate Professor, Neurology, UCSF Weill Institute for Neurosciences

11:50pm: Panel

●      Moderator: Artem Trotsyuk, PhD, HAI Fellow, Instructor Longevity Science 

●      Dena Dubai, Tony Wyss-Coray, Ronjon Nag

  12.25-1.15 Break & lunch

●      We will provide a catered selection of lunch options

1.15pm: Longevity Therapeutics: killing bad cells of aging and rejuvenating the good ones

●       Marco Quarta, PhD, Founder of Rubedo Life Sciences and Turn.bio

1:50pm: Mitochondria applications in aging

●      Vinit Mahajan, Professor of Opthalmology, Advisor Mitrix.bio

2:25pm: Analyzing longevity ventures

●      Correlation vs causation

●      Valuing longevity ventures

2:45pm: Finding financing for longevity ventures, deal terms for investment and M&A

●      Arman Pahlavan, Perkins Coie

●      What do venture firms look for

●       Deal terms for biotechs

●       Biodollar deals

●       Grant sources and applying for grants  

3:20pm: Project Blueprint: Next evolution of human

●      Bryan Johnson and interview by Prof Michael Snyder

4pm: Longevity Company Competition

Company and idea presentations

5pm: End of Symposium